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Anti-cyclic citrullinated peptide (CCP) antibody is a useful marker for the diagnosis and prognosis of rheumatoid arthritis (RA).
Recently, clinical signiﬁcance of follow-up in anti-CCP antibody titer has been pointed out. Thus, we investigated the serial deter-
mination in anti-CCP antibodies titer in RA patients. Six patients with RA, who were followed up for longer than 5 years, were
assessed in anti-CCP antibodies and radiographs (Larsen score). Anti-CCP antibodies in frozen sera were measured using ELISA.
Asaresult,6patientswithRAweredividedintotwogroups:onepossessedhightiterswithoutvariation,andtheotherwaswithout
high titers. Joint damage progressed during observation in 2 out of 3 patients with high anti-CCP titers in a retrospective assess-
ment. In contrast, the RA patient, whose anti-CCP titer decreases although it had been high titer at baseline, did not show increase
in the Larsen score. These ﬁndings suggest that it might be necessary to analyze changes in anti-CCP to predict the prognosis of
joint destruction.
Copyright © 2007 Toshiaki Kogure et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inﬂammatory au-
toimmune disease characterized by progressive cartilage ero-
sion and destruction. Previous investigations have shown
that autoantibodies to a cyclic citrullinated peptide (anti-
CCP)arehighlyspeciﬁcforRA,includingtheearlyform,and
that these antibodies may be of prognostic value as mark-
ers predicting progression to more serious disease [1–3]. Re-
cently,ithasbeenreportedthatseriallydeterminedanti-CCP
performs better than baseline determination for predicting
radiographic progression in patients with RA [4]. Therefore,
we retrospectively investigated the association between vari-
ations in anti-CCP titers and the progression of joint damage
inourRApatients,whohadnotbeentreatedwithanti-TNF-
alpha drugs and tacrolimus hydrate.
2. PATIENTS AND METHODS
Firstly, to conﬁrm the speciﬁcity and sensitivity of anti-CCP
antibodies in our hospital, we assessed anti-CCP titer in RA
or other various autoimmune diseases (see Figure 1)b e f o r e
serial determination in RA.
In the longitudinal observation, anti-CCP antibody was
detected in sera obtained from 6 RA patients who were fol-
lowedupfor5years.Eachserumsamplewasfrozenat −80◦C
andstored.The6-patientproﬁlesatthestartoffollow-upare
demonstrated in Table 1. They fulﬁlled the diagnostic crite-
ria for RA. Radiographic assessment was performed retro-
spectively. Serial radiographs of the hands and feet (standard
ﬁlm on anteroposterior projection) were taken from the start
until year 5 during regular clinical assessments. The radio-
graphs were evaluated according to Larsen and Dale [5]a n d
Lindqvist et al. [6].Anti-CCP antibodies were assessed with
a commercial enzyme-linked immunosorbent assay (ELISA:
second generation; Axis-Shield Diagnostics Limited, UK),
according to the manufacturer’s instructions. In brief, serum
samples were diluted 1 : 100, or more for cases in which the
antibody level was very high with optical densities not falling
within a standard curve at the original dilution. The samples
wereincubatedfor60minutesatroomtemperature.Afterin-
cubation, each well was washed with washing buﬀer 3 times.2 Mediators of Inﬂammation
Table 1: The 6-patient proﬁles in the follow-up study during 5 years.
No. Age/Sex Disease duration∗ Anti-CCP titer Treatment
1 50/f 2.2 High SASP∗∗, MTX∗∗∗,P S L ##
2 65/f 12 High Bucillamine
3 31/f 5 High SASP, MTX
4 48/f 6 Negative Bucillamine
5 51/f 5 Low Bucillamine
6 46/f 2.5 High-negative SASP
∗disease duration (year) at the start of observation;
∗∗salazosulphpiridine; ∗∗∗methotrexate, ##prednisolone.
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Figure 1: Anti-CCP titer in RA (rheumatoid arthritis: 23 females
and 8 males) who fulﬁlled the diagnostic criteria for RA or other
various autoimmune diseases. Autoimmune diseases except for RA,
such as primary Sjogren’s syndrome (PSS; n = 12), systemic lu-
pus erythematosus (SLE; n = 13), mixed connective tissue disease
(MCTD; n = 6), Bechet’s disease (n = 4), systemic sclerosis (SSc;
n = 3), polymyalgia rheumatica (PMR; n = 2), primary biliary
cirrhosis (PBC; n = 3), Wegener’s gnanuloma (WG; n = 1), and
inﬂammatory bowel disease (IBD; n = 3), were also assessed. Two
patients with SSc overlapped with RA.
One hundred ul of substrate were added to each well. After a
30-minute incubation, each sample was measured for its ab-
sorbance at 550nm. Each assay was carried out in duplicate.
3. RESULTS AND DISCUSSION
Anti-CCP titers in patients with RA or other autoimmune
diseases are shown in Figure 1. Anti-CCP was positive in
94.7% of the patients with RA and negative in 88.8% of
the patients with other autoimmune diseases except for RA.
These results are in accordance with the previous report [1].
Two systemic sclerosis (SSc) patients with anti-CCP were
complicated with RA.
Anti-CCP titers changes in the 6 patients are shown in
Figure 2. Three of the patients (no. 1, 2, and 3 in Table 1)
showed a high anti-CCP titer and one patient (no. 4) showed
a low titer over 5 years, without variation. In serum obtained
frompatientno.5,anti-CCPwasnotdetectedduringthedis-
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Figure 2: Anti-CCP titer changes in each patient. The numbers re-
fer to patient no. 5 in Table 1.
ease course. Although anti-CCP titer was high at the start of
observation in patient no. 6, anti-CCP was not detected in
her sera during the succeeding four years.
We show the variations in radiographic damage in each
patient according to Larsen and Dale [5] and Lindqvist et
al. [6]i nFigure 3. The Larsen score increased during obser-
vationin2of3patientswhodemonstratedhightitersofanti-
CCP. Besides, the Larsen score was already high at the start
of observation in the remaining one patient (no. 2). In con-
trast, the Larsen score did not change in patients whose anti-
CCP titer was low or negative. Furthermore, one patient (no.
6), whose anti-CCP titer was high at the start of observation
and was not detected in her sera during the succeeding four
years, also did not show increase in the Larsen score. These
observations conﬁrm that a high anti-CCP titer predisposes
patients toward joint destruction progression, and probably
suggest that decrease in titers of anti-CCP autoantibodies
predicts the suppression of joint damage. Therefore, the
clinical course of the patients with high titer of anti-CCPToshiaki Kogure et al. 3
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Figure 3: The change in Larsen score during observation. Closed
circle (•) indicates the patients with serial high titers in anti-CCP.
The numbers refer to patient no. 5 in Table 1.
antibody may change by the decrease in their titers. How-
ever, these insights raise another problem. Do anti-tumor
necrosis factor (TNF)-alpha drugs facilitate control of radio-
graphic outcomes over the long term in patients with RA ?
Recent studies have reported that treatment with inﬂiximab
decreasedtheserumlevelofrheumatoidfactor(RF)butanti-
CCP antibodies did not [7, 8]. Thus,many investigators have
highlighted the absence of signiﬁcant variations in anti-CCP
titers in patients treated with anti-TNF-alpha drugs in con-
trast with the level of RF. To resolve this problem, further
prospective studies will be required using patients treated
with anti-TNF-alpha drugs.
Finally, the decrease in titers of anti-CCP autoantibod-
ies, even if high titer at baseline, may predict the suppression
of joint damage. Serially determined anti-CCP antibodies as
wellasbaselinedeterminationshouldbeconsideredfromthe
predictable viewpoint.
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